Pembrolizumab
3475-495
Phase 2 mab completed
Quick answer
Pembrolizumab for Advanced Non-Small Cell Lung Cancer is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- completed